Kristina Masson
EVP - Business Operations at Acrivon Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Acrivon Therapeutics Inc., 2 years.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 21, 2026 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ13,729 | $1.79 | $24,575 |
| Nov 21, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ19,904 | $2.30 | $45,779 |
| Nov 14, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ59,765 | $2.24 | $133,874 |
| Nov 14, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ490 | $2.24 | $1,098 |
| Aug 21, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ19,905 | $1.32 | $26,275 |
| Aug 14, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ59,766 | $1.39 | $83,075 |
| Aug 14, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ490 | $1.39 | $681 |
| Feb 14, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ37,152 | $5.42 | $201,364 |
| Feb 14, 2025 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ579 | $5.42 | $3,138 |
| Nov 21, 2024 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ19,910 | $6.44 | $128,220 |
| Aug 14, 2024 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ490 | $7.02 | $3,440 |
| May 14, 2024 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ490 | $8.36 | $4,096 |
| Feb 14, 2024 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ579 | $3.40 | $1,969 |
| Nov 14, 2023 | Acrivon Therapeutics Inc. | Shares withheld for tax | โ1,900 | $5.08 | $9,652 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.